Viromed Medical AG completes acquisition of pharmedix GmbH

• Notarial purchase agreement signed today
• Consolidated revenues are expected to multiply to a low double-digit million euro amount in fiscal year 2025.

Pinneberg, 20 December 2024 – Today, Viromed Medical AG (Ticker: VMED; ISIN: DE000A3MQR65) completed the announced acquisition of pharmedix GmbH by notarized purchase agreement. The acquisition is effective as of 1 January 2025. Following the successful acquisition of pharmedix GmbH, Viromed Medical AG now expects consolidated revenues in the low double-digit million euro range for the 2025 financial year, a significant increase over the previous year.

 

Contact Viromed Medical AG

Uwe Perbandt
CEO
Flensburger Straße 18
25421 Pinneberg
E-Mail: kontakt@viromed-medical.de
www.viromed-medical-ag.de

Marinomed Biotech AG: Extraordinary general meeting approves sale of Carragelose division

• Required majority of shareholders vote in favour of the sale of the Carragelose business unit
• Proceeds from the sale ensure implementation of the restructuring plan and commercialization of the Marinosolv platform
• Dr. Karl Mahler elected to the Supervisory Board

Korneuburg, Austria, 19. December 2024 – Marinomed Biotech AG (VSE:MARI) announces that the majority of shareholders approved the sale of the Carragelose business unit to the French company Unither Pharmaceuticals at today’s extraordinary general meeting. This approval is an important prerequisite for the closing of the transaction. In November 2024, Marinomed signed an agreement on the sale of the Carragelose business, which provides for upfront and milestone payments of in total up to EUR 20 million. Closing of the deal is still subject to other conditions such as approval in accordance with the Investment Control Act.

Furthermore, Dr. Karl Mahler has been elected as member of the Supervisory Board. He holds a doctorate in economics and held several leadership positions in corporate planning and investor relations, including over 20 years as Head of Investor Relations at Hoffman La Roche. After the resignation of Dr. Eva Hofstädter-Thalmann and Dr. Ulrich Kinzel, the Supervisory Board now consists of four members, two women and two men.

All other proposed resolutions of the Management Board and Supervisory Board, including the creation of new authorized and conditional capital, were also approved by large majorities.

“The shareholders’ approval of the sale of the Carragelose business is essential for the Company’s continued existence. Our strategic focus is clearly on the commercialization of the Marinosolv products Budesolv and Tacrosolv and the expansion of the Solv4U service offering. We thank our shareholders for their support and are working hard to lead the Company to profitability,” says Andreas Grassauer, CEO of Marinomed.

Further information on the extraordinary general meeting, including the voting results and the Management Board presentation can be found in the investors section of the corporate website at: https://www.marinomed.com/en/investors-esg/annual-general-meeting.

About Marinomed Biotech AG

Marinomed Biotech AG is an Austrian, science-based biotech company with a growing development pipeline and globally marketed therapeutics. The Company develops innovative patent-protected products in the therapeutic areas immunology and virology based on the platform Marinosolv® and the virus-blocking activity of Carragelose®. The Marinosolv® technology improves the solubility and bioavailability of hardly soluble compounds and is used to develop new therapeutics for autoreactive immune disorders. The virology segment includes Carragelose®-based over-the-counter (OTC) products to prevent and treat respiratory viral infections that are partnered in more than 40 countries. The Company is headquartered in Korneuburg, Austria, and is listed on the Vienna Stock Exchange (VSE:MARI). For further information, please visit: https://www.marinomed.com.

For further inquiries contact:

Marinomed Biotech AG PR & IR: Lucia Ziegler T: +43 2262 90300 158 E-Mail: pr@marinomed.com  E-Mail: ir@marinomed.com

Disclaimer

This press release contains forward-looking statements, which are based on current views, expectations and projections of the management of Marinomed Biotech AG about future events. These forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results, performance or events to differ materially from those described in, or expressed or implied by, such statements. The current views, expectations and projections of the management of Marinomed Biotech AG may be identified by the context of such statements or words such as “anticipate,” “believe”, “estimate”, “expect”, “intend”, “plan”, “project” and “target”. Forward-looking statements are only valid as of the date they are made and Marinomed Biotech AG does not assume any obligation to update, review or revise any forward-looking statements contained in this press release whether as a result of new information, future developments or otherwise. Marinomed, Marinosolv® and Carragelose® are registered trademarks of Marinomed Biotech AG. These trademarks may be owned or licensed in select locations only.

 

Q4 & Financial Year 2023/2024 (July – September 2024)

DOUGLAS Group achieves strong results and strategic progress in financial year 2023/2024

• Strong performance above guidance in FY 2023/2024 (October 2023 to September 2024):
  • Group sales up 8.7% (reported) to 4.45 billion euros (like-for-like, “lfl”: +9.1%)
  • Adj. EBITDA grew 11.4% to 808.6 million euros; adj. EBITDA margin: 18.2% (PY: 17.7%)
  • Continued deleveraging: Leverage ratio of 2.8x as of 30 September 2024
  • Net income improved significantly to 84.0 million euros (PY: 16.7 million euros)
• Strong finish with Q4 top and bottom line clearly ahead of PY:
  • Group sales up 8.7% (reported) to 959.9 million euros (lfl: +9.4%), driven by continued omnichannel growth: Stores contributed 8.3% and E-Com 9.5% growth
  • Adjusted EBITDA up 10.9% to 151.5 million euros, adj. EBITDA margin: 15.8% (PY: 15.5%)
  • Quarterly net income improved significantly to 71.8 million euros (PY: -28.2 million euros)
  • FY 2024/2025 guidance: Sales expected in a range between 4.7 and 4.8 billion euros; expected increase of adj. EBITDA to between 855 and 885 million euros; average Net Working Capital (NWC) expected to amount to less than 5% of Group sales
  • Sander van der Laan, CEO DOUGLAS Group: „I am very happy that we not only delivered yet another year of excellent results, but also exceeded our upgraded guidance while at the same time making continued progress in implementing our growth strategy and ESG initiatives.”

Düsseldorf, 19 December, 2024 – The DOUGLAS Group, Europe’s number one omnichannel destination for premium beauty, has successfully concluded the financial year 2023/2024 with strong results. In the financial year that marked the company’s IPO, the DOUGLAS Group has made steady progress in implementing its growth strategy “Let it Bloom”, significantly deleveraged its balance sheet and sharpened its profile as a leading premium beauty retailer.

In the period from 1 October 2023 to 30 September 2024, the DOUGLAS Group grew sales by 8.7% to 4.45 billion euros (FY 2022/2023: 4.1 billion euros). Both store sales with 8.2% (lfl: +7.5%) and E-Com with +9.8% (lfl: +12.1%) contributed to overall growth. Adj. EBITDA amounted to 808.6 million euros – an increase of 11.4% compared to the prior financial year, and corresponding to an adj. EBITDA margin of 18.2% (FY 22/23: 17.7%). The Group achieved a significantly improved positive net income of 84.0 million euros (FY 22/23: 16.7 million euros). Free Cash Flow (FCF) increased to 524.0 million euros (FY 2022/23: 480.6 million euros).

The DOUGLAS Group therefore exceeded both its initial sales guidance of around 7% growth for the financial year as well as its revised guidance of around 8.5% after it got upgraded in July 2024 following strong first nine months of the financial year. The Group steadily moves towards achieving its mid-term earnings guidance of an expected adj. EBITDA margin of around 18.5%.

Sander van der Laan, CEO of the DOUGLAS Group, said: “I am very happy that we not only delivered yet another year of excellent results, but also managed to exceed our upgraded guidance. At the same time, we accomplished good progress in implementing our growth strategy and sustainability initiatives. Together with our significantly improved financial profile, this provides us with a strong tailwind and robust foundation to further reinforce our leading market position – now and in the years to come. As a result, we have entered the new financial year from a position of strength. Congratulations to the entire team and our four retail brands – you have truly excelled in 2023/2024.”

Strong finish to 2023/2024 provides momentum for financial year 2024/2025

From July to September 2024, the DOUGLAS Group continued to record strong omnichannel growth. Group sales improved by 8.7% (reported) to 959.9 million euros (lfl: +9.4%), to which stores contributed 8.3% and E-Com 9.5%. On a like-for-like base, store sales increased by 7.8% and E-Com by 12.8% compared to the previous year. Adj. EBITDA was up 10.9% to 151.5 million euros (FY 22/23: 136.7 million euros), corresponding to an adj. EBITDA margin of 15.8% (FY 22/23: 15.5%).

On top of a strong fourth quarter, the Group started well into the first quarter of the new financial year. Based on these results, the DOUGLAS Group expects sales to increase to 4.7 billion euros to 4.8 billion euros in the financial year 2024/2025. Growth is expected to be driven by both channels with an anticipated increase of store sales in the mid-single-digit range and an anticipated increase of E‑Com sales in the high-single-digit range. The Group expects an adj. EBITDA of 855 to 885 million euros. Average NWC is expected to amount to less than 5% of total Group sales in 2024/25.

The DOUGLAS Group further expects an increase in the consolidated net income to  225 to 265 million euros in the financial year 2024/25. This assumption is based on an improvement in the above mentioned adj. EBITDA and in the financial result due to the completed refinancing in the wake of the successful IPO, as well as depreciation and a tax rate at the average level of previous years. The expected strong increase in the consolidated net income and a continued healthy free cash flow development should result in further deleveraging. Therefore, the DOUGLAS Group makes steady progress towards achieving a leverage ratio of around 2.0x at the end of the calendar year 2025.

Sustained omnichannel success as ‘Let it Bloom’ strategy unfolds

Sales growth in the financial year 2023/2024 resulted from positive developments across all segments, with DACHNL, CEE (Central Eastern Europe) and PD/NB (Parfumdreams / Niche Beauty) growing particularly strongly and double-digit. The online channel continued to gain traction in CEE as E‑Com grew above 20% for the second consecutive year on top of double-digit growth in store sales.

Underlined by sustained strong performance across all channels and in line with the growth strategy “Let it Bloom”, the Group continues to advance its successful omnichannel model both strategically and operationally. In a multi-phase rollout over the next years – starting in early 2025 in the Netherlands –, the customer loyalty program will be fully redesigned and harmonized internationally. The new program will include new Beauty Card tiers, facilitated personalization and omnichannel shopping activation as well as additional benefits rewarding customers for purchases.

At the same time, the company continues to develop its store network: In the financial year 2023/2024, the DOUGLAS Group has opened 54 new stores and refurbished 144 existing ones (including relocations). 20 stores were closed in the same period, which included six franchise stores. This November, a new Flagship store opened in a prestige location in Zagreb, Croatia. Further upcoming strategic openings in the financial year 2024/2025 include Antwerp, Salzburg and Berlin.

Major progress in ESG initiatives

The company has achieved major milestones in all three fields of action of its sustainability strategy on its path to become a leading premium beauty retailer in sustainability:

• People: In 2024, the DOUGLAS Group was officially certified a “GREAT PLACE TO WORK” for the first time. It also achieved top positions in Forbes’ “World’s Top Companies for Women” study: The DOUGLAS Group ranked #1 among global Retail & Wholesale companies, #3 in the global cross-industry list, as well as #1 in Germany, all underlining the Group’s strong commitment to creating a work environment that empowers and inspires women.
• Planet: The DOUGLAS Group continues to successfully reduce both its energy consumption and its Scope 1 and 2 emissions and has achieved good progress in 2023/24 compared to the previous financial year as it steadily improves sustainability tracking and measuring. It further initiated the Group-wide installation of smart meters in stores and switched to organic brown B2C delivery boxes in the DACH region with the highest possible share of recycled paper (between 81% and 85%).
• Products: Based on an assessment of already 70% of its Corporate Brands range in terms of its ecological footprint, the DOUGLAS Group is confident to achieve its CO2 targets for its Corporate Brands. In May 2024, the company also defined and implemented a sustainable packaging policy for its Corporate Brands.

Start of the financial year 2024/2025

The DOUGLAS Group started well into the new financial year 2024/2025 with the important pre-Christmas sales period including additional sales highlights Singles’ Day and Beauty Friday.

 

Overview Financial Results

Q4 FY 2023/2024	Q4 2022/2023	Q4 2023/2024	Change (reported)	Change (lfl)
Sales	€883.1m	€959.9m	+8.7%	+9.4%
Stores	€615.4m	€666.6m	+8.3%	+7.8%
E-Commerce	€267.8m	€293.2m	+9.5%	+12.8%
E-Commerce % of sales	30.3%	30.6%	+0.2ppts
Segment DACHNL	€410.4m	€460.5m	+12.2%	+12.7%
Segment France	€161.0m	€160.1m	-0.6%	-1.0%
Segment SE	€130.2m	€143.5m	+10.2%	+9.7%
Segment CEE	€127.5m	€146.4m	+14.8%	+11.6%
Segment PD/NB	€40.1m	€43.1m	+7.4%	+7.4%
Adjusted EBITDA	€136.7m	€151.5m	+10.9%
Net Income	-€28.2m	€71.8m	Pos.

 

FY 2023/2024	FY 2022/2023	FY 2023/2024	Change (reported)	Change (lfl)
Sales	€4,093.9m	€4,451.0m	+8.7%	+9.1%
Stores	€2,771.4m	€2,999.5m	+8.2%	+7.5%
E-Commerce	€1,322.4m	€1,451.4m	+9.8%	+12.1%
E-Commerce % of sales	32.3%	32.6%	+0.3ppts
Segment DACHNL	€1,871.9m	€2,073.1m	+10.7%	+11.0%
Segment France	€813.5m	€838.2m	+3.0%	+2.5%
Segment SE	€625.6m	€665.8m	+6.4%	+5.7%
Segment CEE	€556.4m	€652.1m	+17.2%	+14.6%
Segment PD/NB	€171.6m	€190.2m	+10.8%	+11.1%
Adjusted EBITDA	€725.9m	€808.6m	+11.4%
Liquidity (30 September)	€262.3m	€98.9m	-62.3%
Net Income	€16.7m	€84.0m	+404.2%

Segment Overview: DACHNL (Austria, Belgium, Germany, Switzerland, The Netherlands), France (France, Monaco), SE / Southern Europe (Andorra, Croatia, Italy, Portugal, Slovenia, Spain), CEE / Central Eastern Europe (Bulgaria, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, Slovakia), PD/NB (Parfumdreams, Niche Beauty)

 

About the DOUGLAS Group

The DOUGLAS Group, with its commercial brands DOUGLAS, NOCIBÉ, Parfumdreams and Niche Beauty, is the number one omnichannel premium beauty destination in Europe. The DOUGLAS Group is inspiring customers to live their own kind of beauty by offering a unique assortment online and in around 1,880 stores. With unparalleled size and access to customers, the DOUGLAS Group is the partner of choice for brands and offers a premium range of selective and exclusive brands as well as own corporate brands. The assortment includes fragrances, color cosmetics, skin care, hair care, accessories as well as beauty services. Strengthening its successful omnichannel positioning while consistently developing superior customer experience is at the heart of the DOUGLAS Group strategy “Let it Bloom”. The winning business model is underpinned by the Group’s omnichannel proposition, leading brands, and data capabilities. In the financial year 2023/2024, the DOUGLAS Group generated sales of around 4.5 billion euros and employed around 19,200 people across Europe. The DOUGLAS Group (Douglas AG) is listed at the Frankfurt Stock Exchange.

For further information please visit the DOUGLAS Group Website.
 

Investor Contact

Stefanie Steiner
Director Investor Relations and M&A
Phone: +49 211 16847 8594
Mail: ir@douglas.de

 

Press Contact

Peter Wübben
SVP Group Communications & Sustainability
Phone: +49 211 16847 6644
Mail: newsroom@douglas.de

Not for release, publication or distribution, directly or indirectly, in or into the United States of America, Australia, Canada or Japan or any other jurisdiction in which such release, publication or distribution would be unlawful. The important notes at the end of this announcement need to be observed.

 

Cantourage Group SE exports medical craft cannabis for the first time to the growth market of Poland; cooperation with the wholesaler PharmaVitae to be expanded in 2025

 

Berlin, December 19, 2024 – Cantourage Group SE (hereinafter “Cantourage,” ISIN: DE000A3DSV01, www.cantourage.com), Europe’s leading listed cannabis company, is offering its high-quality cannabis products in Poland together with the Polish pharmaceutical wholesaler PharmaVitae from today on. To this end, Cantourage has signed a long-term supply contract with the company.

The partnership and distribution will begin with Cantourage’s “Mac 1,” a cannabis strain that is very popular with patients in Germany and the UK and has proven itself over many years. The collaboration is to be continuously expanded in 2025 to include additional products from the Cantourage portfolio.

“We are very pleased to be working with PharmaVitae to make it even easier for patients in Poland to access high-quality cannabis flowers safely. With our ‘Mac 1,’ we have already set new standards for the quality of medical cannabis in Germany and the UK in recent years – we are delighted to be able to continue this success story in Poland as well,” commented Bernhard Retzer, Global Sales Director at Cantourage. “In the months to come, we will be adding further varieties from our top growers to maximize our growth opportunities in the dynamic Polish market in 2025 and beyond. PharmaVitae, with its many years of experience, extensive distribution network and shared vision of ‘high-quality medical cannabis for all,’ is the ideal partner for this.”

PharmaVitae has expanded its own network of customers for medical cannabis quite quickly: Shortly before the end of 2024, it comprised more than 1,200 pharmacies (2023: approx. 400 pharmacies) that will be able to offer Cantourage products to their customers in the future. This growth demonstrates the broad demand for and acceptance of medical cannabis as a versatile pharmaceutical in Poland.

“According to our estimates, approximately 4.6 tons of medical cannabis were delivered by wholesalers to pharmacies in Poland in 2023. For 2024, we expect growth of well over 30 percent in the overall market – the 5-ton mark was already cracked by the end of September,” said Małgorzata Leman-Borsuk, CEO of PharmaVitae, in reference to the Polish market. “Cantourage has impressively demonstrated in the past that it can scale its capacities very quickly and adapt to rapidly increasing demand. In addition to the highest standards of product safety and quality, this reliability and flexibility is extremely important for us as a wholesaler to ensure flourishing and sustainable business relationships in this growth field.”

 

About Cantourage

Cantourage is a leading European producer and distributor of cannabis flowers and cannabis-based medicinal preparations and drugs. The Berlin-based company was founded in 2019 by industry pioneers Norman Ruchholtz, Dr. Florian Holzapfel and Patrick Hoffmann. With an experienced management team and its “Fast Track Access” platform, Cantourage enables producers from around the world to become part of the growing European medical cannabis market faster, easier and more cost-effectively by processing and distributing their cannabis raw materials and extracts. In this context, Cantourage ensures compliance with the highest European pharmaceutical quality standards at all times. The company offers pharmaceutical-grade products in all relevant market segments: dried flower, extracts, dronabinol and cannabidiol. Cantourage was listed on the Frankfurt Stock Exchange on 11 November 2022 and is listed under ticker symbol “HIGH.”

Further information: www.cantourage.com

 

About PharmaVitae
PharmaVitae is a privately owner Polish company founded in 2011 that specializes in the import and distribution of Rx and OTC pharmaceuticals, medical devices and cosmetics. The company supplies pharmacies, doctors, hospitals, clinics and drugstores throughout Poland and reported annual sales of PLN 80 million in 2023. PharmaVitae ensures efficient and reliable distribution with its modern, WDL-certified warehouse that meets all GDP requirements and can accommodate up to 2,000 pallets.

Further information: https://pharmavitae.com.pl/

 

This announcement does not constitute a public offer or an advertisement for a public offer to sell securities, in particular not within the meaning of Regulation (EU) 2017/1129 (Prospectus Regulation).

 

Press contact at Cantourage:

Frederick Steudemann
Tel. +49 (0)30 4701 350 – 50
steudemann@cantourage.com

 

Classification of First Berlin Equity Research GmbH to MPH Health Care AG

Company Name:	MPH Health Care AG
ISIN:	DE000A289V03
Reason for the research:	9M Kennzahlen
Recommendation:	Kaufen
from:	18.12.2024
Target price:	€108
Target price on sight of:	12 Monate
Last rating change:	–
Analyst:	Ellis Acklin

First Berlin Equity Research hat ein Research Update zu MPH Health Care AG (ISIN: DE000A289V03) veröffentlicht. Analyst Ellis Acklin bestätigt seine BUY-Empfehlung und bestätigt sein Kursziel von EUR 108.

Zusammenfassung:
MPH meldete mit den Neunmonatskennzahlen einen guten Wertzuwachs. Der Nettoinventarwert (NAV) stieg in der 9M Periode um 20% und im Jahresvergleich um 39% auf €300 Mio. Der NAVPS bewegte im Gleichschritt dazu und landete bei €70,10. Die Aktien von M1 Kliniken legten im Zeitraum von Januar bis September um 50% zu, angetrieben von der positiven Dynamik des florierenden Prejuvination-Geschäfts. Das Management von CR Energy geht davon aus, dass sich die Ergebnisse des Jahres 2024 in das zweite Halbjahr verschieben werden, wies jedoch darauf hin, dass ihre Beteiligungen Terrabau und Solartec im ersten Halbjahr einen Gewinn von €9,5 Mio. erzielten. Die CRE-Aktien lagen im Neunmonatszeitraum rund 18% im Minus. M1 eröffnet weiterhin Schönheitskliniken (jetzt: 63 Standorte) auf dem Weg zu ihrem Ziel von 150 bis 200 Zentren bis JE29, und die CRE-Geschäftsbereiche Clean Energy und hochwertiger, erschwinglicher Wohnraum florieren trotz eines weiteren Gegenwinds für die Immobilienmärkte. Wir bekräftigen unser Kursziel von €108 und unser Kaufen-Votum.

First Berlin Equity Research has published a research update on MPH Health Care AG (ISIN: DE000A289V03). Analyst Ellis Acklin reiterated his BUY rating and maintained his EUR 108 price target.

Abstract:
MPH reported good value uplift with nine month reporting. NAV rose some 20% during the first nine months of ’24 and was up 39% Y/Y to €300m, while NAVPS moved in lockstep landing at €70.1. M1 Kliniken shares were up 50% during the January-to-September period spurred by the positive momentum of the thriving prejuvination business. Meanwhile, CR Energy management expect 2024 results to be backloaded into H2 but noted that the Terrabau and Solartec holdings racked up €9.5m in profit during H1/24. CRE shares were down around 18% at the 9M juncture. M1 continues to open clinics (now: 63) on the way to its YE29 goal of 150 to 200 centres, and CRE’s clean energy and quality, affordable housing businesses continue to flourish, despite another headwind year for the property markets. We stick to our Buy rating with an unchanged €108 TP.

Bezüglich der Pflichtangaben gem. §34b WpHG und des Haftungsausschlusses siehe die vollständige Analyse.
 

You can download the research here: http://www.more-ir.de/d/31569.pdf

Contact for questions:
First Berlin Equity Research GmbH
Herr Gaurav Tiwari
Tel.: +49 (0)30 809 39 686
web: www.firstberlin.com
E-Mail: g.tiwari@firstberlin.com

The European industrial hemp and cannabis group SYNBIOTIC SE (ISIN DE000A3E5A59 | WKN A3E5A5) announced a strategic partnership with GOC NEXUS OPERATIONS GmbH on 13 December 2024. This collaboration marks a significant step in the further development and optimisation of cannabis processing in Europe. As part of this partnership, SYNBIOTIC will make a strategic investment in GOC NEXUS OPERATIONS GmbH, which will use a globally innovative process for the microbiological decontamination of cannabis GACP raw materials into EU GMP medicinal products in Germany.

Microbiological decontamination is currently one of the biggest challenges for producers of medicinal cannabis. The innovation here lies in the use of cold plasma, which is already widely used in industry and medicine. The ability to clean surfaces and kill microbes while protecting the target structures makes cold plasma a valuable tool in various fields. Due to the comprehensive IP protection for the cold plasma treatment of cannabis in combination with a worldwide application licence, the parent company GOC NEXUS Holding has exclusive access rights in the field of cannabis processing. The technology combines several advantages regarding the decontamination of cannabis. It is an effective and environmentally friendly innovation compared to conventional disinfection methods and will revolutionise the processing of cannabis in the coming years and represent a new gold standard.

The technology is the first sustainable solution as it does not require the use of ionising radiation, heat or chemicals, produces no environmentally hazardous waste products and uses minimal energy. Cold plasma produces reactive species that can effectively kill bacteria, viruses and fungi without damaging the plant structure. This is particularly important with cannabis, as the quality and integrity of the product is vital to the entourage effect.

Unlike many chemical disinfectants, cold plasma-treated cannabis is free of chemical residues after treatment. This makes it safer for the environment and patients. The process enables fast decontamination processes and therefore short production times. This gentle technology preserves the original organoleptic properties of the product, such as taste, smell, structure, colour and effect. The process can be integrated relatively easily into existing supply chains, which makes it attractive for manufacturers.

The technology was originally adapted in Canada for the processing of cannabis and has already been tested by numerous Canadian customers. Due to the high demand, a centre for the consumer cannabis market has already been set up in Canada and is currently being put into operation. At the same time, the technology is being validated at the Laupheim site in Germany by GOC NEXUS OPERATIONS for EU GMP certification, which will be completed by mid-2025.

In addition, GOC NEXUS OPERATIONS is already preparing for vertical integration. To this end, there are plans to supplement contract manufacturing in the area of packaging and market release of pharmaceuticals. This combination will enable GOC NEXUS OPERATIONS to map all processes downstream of pre-drying for its partner SYNBIOTIC.

“We are very pleased to be working with GOC NEXUS and combining our strengths. Our MedCan subsidiaries such as WEECO Pharma can now offer their customers organoleptically enhanced products while safely meeting pharmaceutical standards in terms of microbiology,” said Daniel Kruse, Managing Director SYNBIOTIC. “This partnership is an important step in our strategy to grow through innovation and collaboration.”

“The collaboration with SYNBIOTIC opens up new opportunities and strengthens our ability to offer first-class services,” added Dr David Surjo, Managing Director of the GOC NEXUS companies. “We look forward to our joint success and the positive impact this partnership will have for patients in Germany, enabling us to offer patients premium radiation-free products through reliable supply chains.”

The first production facility is to be built at the new site in Laupheim, which will serve as a blueprint for future global scaling. To this end, the company has developed a modular concept for the process environment that will facilitate future scaling and significantly accelerate the establishment of new production facilities. Talks are already underway with international partners to expand the business model.

About GOC NEXUS OPERATIONS
GOC NEXUS OPERATIONS specialises in the pharmaceutical contract manufacturing of medicinal cannabis in Germany along the value chain and will in future cover all process steps from pre-drying to market release. It is a subsidiary of GOC NEXUS Holding, which is the licence holder for the cold plasma treatment of cannabis.

Publisher
SYNBIOTIC SE
Daniel Kruse
Managing Director
Münsterstraße 336
40470 Düsseldorf
Germany

Media Contact
Rüdiger Tillmann
SYNBIOTIC
Public Relations Manager
E-mail ruediger.tillmann@synbiotic.com
Mobile +49 170 9651451
c/o JOLE.group

About SYNBIOTIC
SYNBIOTIC is a publicly listed group of companies in the hemp and cannabis sector with a buy-and-build investment strategy focussed on the EU.
The Group covers the entire value chain from cultivation to production and retail – from the field to the shelf. The subsidiaries’ core businesses are research and development, production and the commercialisation of hemp, CBD and cannabis products.
SYNBIOTIC is pursuing a clear pan-European strategy to further expand along the value chains of its business areas – hemp and CBD, medical cannabis and consumer cannabis – and thus cover the relevant growth markets while increasing opportunities for investors through diversification.

Marinomed Biotech AG: Requirements for successful completion of the restructuring proceedings achieved

• Funds deposited for cash quota and to cover legal costs
• European Investment Bank (EIB) agrees to standstill declaration
• Implementation of the restructuring plan and the Company’s sustainable continued existence are to be secured by the sale of the Carragelose business

Korneuburg, Austria, 17. December 2024 – Marinomed Biotech AG (VSE:MARI) announces that all necessary conditions for the completion of the ongoing restructuring proceedings without self-administration have been met. The funds for the cash quota and for the costs of the proceedings have been deposited with the insolvency administrator. Within the next two weeks, the creditors’ cash quotas will be paid out from these funds. In addition, a standstill agreement has been concluded with the EIB for the payment of the cash quota until the end of April 2025. The standstill was necessary because Marinomed will only receive the first partial payment from the sale of the Carragelose business after the closing. This can take up to three months. All requirements have thus been met to end the restructuring proceedings and the administration by the insolvency administrator. 

At the final court hearing on November 14, 2024, all present creditors approved the submitted restructuring plan. The plan provides for a quota of 30% payable within the next two years. If milestone payments from the sale of the Carragelose business exceed planned revenues during this period, a super quota of up to 7% will be distributed. As reported previously, Marinomed has also entered into an agreement with the EIB for the planned issue of a convertible bond in the amount of kEUR 424.

A key element of the fulfillment of the restructuring plan is the already signed sale of the Carragelose business to Unither Pharmaceuticals. The closing of the transaction is, among other things, subject to shareholder approval. The approval is expected to be obtained at an extraordinary general meeting on December 19, 2024. Furthermore, the sale is intended to finance ongoing operations and the commercialization of the Marinosolv projects. Necessary funds have been secured through cost saving measures, the execution of two capital increases, the issuance of the convertible bond to the EIB and cash flow from operating activities.

“We have experienced very challenging months. Despite the difficulties, we have been able to develop a restructuring plan that provides an acceptable solution for our creditors and ensures the stable financing of the Company. The two capital increases that have been carried out are also significant for securing our cash situation. We are grateful for the continued support and trust placed in us,” says Andreas Grassauer, CEO of Marinomed.

“The proceeds of up to EUR 20 million from the sale of the Carragelose business are sufficient to finance the restructuring plan, the commercialization of the Marinosolv projects and the further development of the Solv4U unit. With this sale, we are therefore laying the foundation for the long-term positive development of the Company,” adds Pascal Schmidt, CFO of Marinomed.

About Marinomed Biotech AG

Marinomed Biotech AG is an Austrian, science-based biotech company with a growing development pipeline and globally marketed therapeutics. The Company develops innovative patent-protected products in the therapeutic areas immunology and virology based on the platform Marinosolv® and the virus-blocking activity of Carragelose®. The Marinosolv® technology improves the solubility and bioavailability of hardly soluble compounds and is used to develop new therapeutics for autoreactive immune disorders. The virology segment includes Carragelose®-based over-the-counter (OTC) products to prevent and treat respiratory viral infections that are partnered in more than 40 countries. The Company is headquartered in Korneuburg, Austria, and is listed on the Vienna Stock Exchange (VSE:MARI). For further information, please visit: https://www.marinomed.com.

For further inquiries contact:

Marinomed Biotech AG PR & IR: Lucia Ziegler T: +43 2262 90300 158 E-Mail: pr@marinomed.com  E-Mail: ir@marinomed.com

Disclaimer

This press release contains forward-looking statements, which are based on current views, expectations and projections of the management of Marinomed Biotech AG about future events. These forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results, performance or events to differ materially from those described in, or expressed or implied by, such statements. The current views, expectations and projections of the management of Marinomed Biotech AG may be identified by the context of such statements or words such as “anticipate,” “believe”, “estimate”, “expect”, “intend”, “plan”, “project” and “target”. Forward-looking statements are only valid as of the date they are made and Marinomed Biotech AG does not assume any obligation to update, review or revise any forward-looking statements contained in this press release whether as a result of new information, future developments or otherwise. Marinomed, Marinosolv® and Carragelose® are registered trademarks of Marinomed Biotech AG. These trademarks may be owned or licensed in select locations only.

 

Classification of First Berlin Equity Research GmbH to M1 Kliniken AG

Company Name:	M1 Kliniken AG
ISIN:	DE000A0STSQ8
Reason for the research:	9M Hauptkennzahlen
Recommendation:	Kaufen
from:	17.12.2024
Target price:	€28
Target price on sight of:	12 Monate
Last rating change:	–
Analyst:	Ellis Acklin

First Berlin Equity Research hat ein Research Update zu M1 Kliniken AG (ISIN: DE000A0STSQ8) veröffentlicht. Analyst Ellis Acklin bestätigt seine BUY-Empfehlung und bestätigt sein Kursziel von EUR 28,00.

Zusammenfassung:
Das florierende Beauty-Geschäft von M1 Kliniken blieb auch im 3. Quartal die tragende Säule des Konzerns und ebnete den Weg für ein gutes Umsatz- und Ergebniswachstum. Der Konzernumsatz lag nahe an unserer Prognose, aber das operative Ergebnis übertraf unsere Schätzung um 9%, da das Beauty-Segment ein EBIT-Wachstum von 41% J/J verzeichnete. Die Hauptkennzahlen des Segments Trade blieben mit einer EBIT-Marge von 2% bei einem Umsatz von €67 Mio. im Septemberquartal stabil. M1 betreibt nun 63 medizinische Fachzentren, nachdem in diesem Jahr 4 neue Praxen in Deutschland und eine weitere in Österreich eröffnet wurden. Wir haben unsere Schätzungen für 2024 angehoben, um der 9M/24-Outperformance Rechnung zu tragen, und behalten unsere Kaufempfehlung mit einem unveränderten Kursziel von €28 bei.

First Berlin Equity Research has published a research update on M1 Kliniken AG (ISIN: DE000A0STSQ8). Analyst Ellis Acklin reiterated his BUY rating and maintained his EUR 28.00 price target.

Abstract:
M1 Kliniken’s thriving Beauty business remained the group mainspring in Q3 paving the way for good sales and earnings growth. Group turnover was close to FBe, but operating income overshot our estimate by 9% on the back of 41% Y/Y EBIT growth registered by the Beauty segment. Meanwhile, Trade segment KPIs remained stable with a 2% EBIT margin on €67m in turnover for the September quarter. M1 now operates 63 treatment centres after opening 4 new practices in Germany and another one in Austria this year. We have nudged our 2024 targets higher to account for the 9M/24 outperformance and remain Buy-rated on M1 with an unchanged €28 target price.

Bezüglich der Pflichtangaben gem. §34b WpHG und des Haftungsausschlusses siehe die vollständige Analyse.

 

You can download the research here: http://www.more-ir.de/d/31553.pdf

Contact for questions:
First Berlin Equity Research GmbH
Herr Gaurav Tiwari
Tel.: +49 (0)30 809 39 686
web: www.firstberlin.com
E-Mail: g.tiwari@firstberlin.com